Four quick questions. One recommendation.
By treatment area
Formulated to work with light — not just alongside it. Young Goose collab. EWG Green. Made in USA.
About the research on this page. The studies cited here investigate photobiomodulation (PBM) as a therapeutic modality and the specific wavelengths used in PBM research — not Mito Red Light devices. The wavelengths in our panels were chosen because the peer-reviewed PBM literature supports them. Evidence levels and study counts reflect the broader research base, not studies of our products. See the full methodology note at the bottom of this page.
Photobiomodulation (PBM) applied to the skin operates primarily through the absorption of red (630–660 nm) and near-infrared (810–850 nm) light by mitochondrial chromophores—particularly cytochrome c oxidase—in dermal and epidermal cells. This photochemical interaction increases mitochondrial membrane potential, elevates ATP synthesis, and transiently modulates reactive oxygen species (ROS) levels, collectively triggering downstream signaling cascades that stimulate fibroblast proliferation, collagen and elastin production, and accelerated tissue remodeling.
A substantial body of peer-reviewed research, including randomized controlled trials and systematic reviews, has investigated PBM across a range of dermatological applications: photoaging and wrinkle reduction, acne vulgaris, post-procedural wound healing, hyperpigmentation, hair loss, and psoriasis. The evidence base is most robust for wound healing and collagen stimulation, with several well-designed RCTs reporting statistically significant improvements in skin texture, wrinkle depth, and dermal collagen density following repeated low-level red light exposures.
Effective parameters reported across the literature typically involve wavelengths of 630–660 nm for superficial skin targets or 810–850 nm for deeper dermal penetration, irradiance values of 10–50 mW/cm², and energy doses of 3–10 J/cm² per session. Treatment protocols generally span 4–12 weeks with sessions 3–5 times per week. The evidence suggests that appropriate dosing is critical: both insufficient and excessive energy delivery may reduce or negate therapeutic benefit, a phenomenon known as the biphasic dose-response (Arndt-Schulz Law).
In skin tissue, PBM light is absorbed primarily by cytochrome c oxidase in keratinocytes and dermal fibroblasts, driving a cascade of photochemical events: increased electron transport chain efficiency leads to elevated ATP production and a controlled modulation of ROS. At therapeutic doses, this stimulates fibroblast activation and proliferation—the cells responsible for synthesizing the structural proteins of the dermis. Activated fibroblasts upregulate transcription of COL1A1 and COL3A1 genes, boosting type I and type III collagen production. Concurrently, PBM modulates matrix metalloproteinase (MMP) activity to reduce excess collagen degradation, and upregulates transforming growth factor-beta (TGF-β), a key driver of dermal remodeling. In the epidermis, PBM accelerates keratinocyte migration for wound re-epithelialization, reduces inflammatory cytokines (IL-1β, TNF-α), and may suppress melanogenesis pathways relevant to hyperpigmentation treatment.
Studies in this category commonly demonstrate:
A curated selection from 503+ indexed studies.
Participants received bi-weekly PBM treatments for 9 weeks. Blinded assessments and profilometry confirmed statistically significant improvements in periorbital wrinkles, skin roughness, and overall complexion compared to sham controls. Collagen density increased on biopsy.
View on PubMed →Meta-analysis found significant reductions in inflammatory lesion counts with both blue and red/near-infrared light. Red light demonstrated superior anti-inflammatory effects. Combination blue/red therapy showed greatest overall reduction in lesion counts. No serious adverse events reported.
View on PubMed →Skin biopsies at 12 weeks showed a statistically significant 35% increase in type I collagen fiber density vs. sham group. Clinical photography and profilometry confirmed reduced wrinkle depth. The authors concluded that 660 nm LED is a safe and effective non-invasive collagen-stimulation modality.
View on PubMed →Standardized wounds in the treatment group showed a 29% faster re-epithelialization rate (days to full closure) compared to untreated controls. Histological analysis confirmed increased keratinocyte proliferation and reduced inflammatory infiltrate in treated wounds.
View on PubMed →Treated subjects demonstrated a statistically significant increase in mean terminal hair density (hairs/cm²) vs. sham. Hair shaft caliber also increased. The device was FDA-cleared based partly on this trial. Mechanism proposed includes enhanced follicular keratinocyte proliferation via cytochrome c oxidase activation.
View on PubMed →Subjects receiving PBM immediately post-laser resurfacing showed significantly reduced erythema, edema, and pain scores at 48–72 hours compared to laser-only controls. Time to re-epithelialization was reduced by an average of 2 days. Side-effect profiles were similar between groups.
View on PubMed →Based on analysis of 503+ peer-reviewed studies:
| Parameter | Typical Range | Notes |
|---|---|---|
| Wavelength (superficial target) | 630–660 nm | Red light range; optimal for epidermis and upper dermis; most studied for collagen stimulation, acne, and texture |
| Wavelength (deeper dermal target) | 810–850 nm | Near-infrared; penetrates to deeper dermis and subcutaneous tissue; preferred for wound healing and deeper collagen remodeling |
| Irradiance | 10–50 mW/cm² | Lower irradiance for longer sessions; higher irradiance for shorter delivery; both can achieve equivalent doses at therapeutic ranges |
| Energy dose per session | 3–10 J/cm² | Established therapeutic window; doses below 1 J/cm² or above 20 J/cm² may reduce efficacy (biphasic dose-response) |
| Session frequency | 3–5× per week | Most clinical protocols use every-other-day or 3×/week for anti-aging; daily use shown effective for wound healing |
| Treatment duration | 4–12 weeks | Collagen remodeling studies typically run 8–12 weeks; wound healing improvements measurable within days to 2 weeks |
The most studied wavelengths for skin applications are 630–660 nm (red light) and 810–850 nm (near-infrared). Red wavelengths are preferentially absorbed by superficial dermal and epidermal tissue and are most commonly studied for collagen synthesis, acne, and surface-level photoaging. Near-infrared wavelengths penetrate more deeply and are frequently used in wound healing and deeper tissue remodeling research. Many clinical protocols combine both ranges.
Yes. Multiple randomized controlled trials (RCTs) have been published demonstrating statistically significant improvements in collagen density, wrinkle depth, and skin texture following repeated PBM treatments in human subjects. A notable example is a 2014 RCT (n=136) published in Photomedicine and Laser Surgery which showed improvements in periorbital wrinkles and skin roughness compared to sham controls confirmed by blinded assessors and profilometry.
Results depend on the application. For wound healing and post-procedure recovery, improvements in re-epithelialization and inflammation reduction can be observed within 3–7 days of treatment. For collagen remodeling and anti-aging outcomes (wrinkle reduction, texture improvement), clinical studies typically show measurable changes after 8–12 weeks of consistent treatment, as collagen synthesis and remodeling are inherently slow biological processes.
The evidence suggests LED-based PBM devices can produce comparable biological effects to low-level laser therapy (LLLT) when delivering equivalent photon doses (J/cm²) at the same wavelengths. The key parameter is the dose delivered to the target tissue, not the coherence of the light source. That said, some clinical applications (e.g., targeted spot treatments) may favor laser devices for spatial precision, while LED panels are advantageous for larger treatment areas.
Published skin studies most commonly report energy doses in the range of 3–10 J/cm² per session, delivered at irradiances of 10–50 mW/cm². This places typical session durations at 3–15 minutes for red/NIR LED panels. The biphasic dose-response (Arndt-Schulz Law) means that both under-dosing and over-dosing can reduce efficacy; doses consistently above 20 J/cm² per session may inhibit rather than stimulate cellular activity in many in vitro and animal models.
Several RCTs and a 2021 systematic review and meta-analysis have investigated PBM for acne vulgaris. Red light (630–660 nm) reduces inflammatory lesion counts primarily through anti-inflammatory mechanisms—lowering IL-1β and TNF-α in sebaceous tissue—while blue light (415 nm) targets Cutibacterium acnes via porphyrin photoexcitation. Combination blue/red therapy has shown the greatest lesion reduction in controlled studies. PBM is generally regarded as an adjunctive, not standalone, acne treatment in current dermatological practice.
At the doses used in published clinical studies (3–10 J/cm², 630–850 nm), red and near-infrared light therapy has a well-established safety profile in skin research. Unlike UV light, wavelengths in the red and near-infrared range do not carry sufficient photon energy to cause DNA strand breaks or ionizing radiation damage. No serious adverse events have been reported in any major RCT or systematic review of PBM for dermatological applications. Appropriate eye protection is recommended during treatment near the face.
All — studies in this category from the PBM research database.
Search all 10,068+ studies across all categories: Open the Full Evidence Explorer →
The published research indexed and referenced on this page studies photobiomodulation (PBM) as a therapeutic modality and the specific wavelengths used in those studies — not Mito Red Light devices specifically. The wavelengths used across our panels were chosen because the peer-reviewed PBM literature supports them: this is where published evidence is deepest, where dosing parameters have been characterized in human studies, and where clinical guidelines (such as WALT for inflammation and pain) exist. Mito Red Light has not funded or conducted registered clinical trials on our specific devices, and the study counts referenced here reflect the broader PBM research base — not studies of our products.
Evidence levels follow GRADE methodology. Study counts reflect peer-reviewed photobiomodulation research drawn from major scientific literature databases, peer-reviewed journals, and other published research repositories. PBM response varies meaningfully by person, tissue, condition, dose, wavelength, and session timing; outcomes reported in the published literature may not be replicable for every user. Mito Red Light devices are not intended to diagnose, treat, cure, or prevent any disease. If you have a medical condition or are under a physician’s care, please consult your healthcare provider before beginning any photobiomodulation regimen.
